Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 27

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 27
---
 and
are granted at an exercise price equal to the average closing sales price per ordinary share on the TASE over the thirty trading day period
preceding the subject date (but not less than “fair market value” with respect to grantees subject to U. S. tax). All option
grants to directors prior to August 10, 2021, are subject to the terms of our 2013 Share Option Plan and were granted at an exercise price
equal to the higher of (i) the average closing price of our ordinary shares on the TASE during the 30 trading days prior to the date of
option allocation, plus 5% and (ii) the closing price of our ordinary shares on the TASE on the date of option allocation. All such options
expire 10 years following the date of grant thereof.

Information regarding the options to purchase our ordinary shares
(including number of options, exercise price and expiration date of all such options) held by each of our directors and executive officers
who beneficially owns our ordinary shares, after including ordinary shares underlying options held by them, which, as of March 17, 2024,
were exercisable or exercisable within 60 days, appears in the beneficial ownership table in Item 7. A below and in the footnotes thereto.

84

Share Option and Incentive Plans

Company Option and Incentive
Plans

We maintain four share option and incentive plans: Evogene Ltd.
2002 Share Option Plan, Evogene Ltd. 2003 Key Employee Share Incentive Plan, Evogene Ltd. 2013 Share Option Plan, and Evogene Ltd. 2021
Share Incentive Plan, or the 2021 Plan. No new grants will be made under the first three plans, although outstanding awards under those
plans remain subject to the terms of those plans. All such option and incentive plans provide for the grant of options to purchase our
ordinary shares, and the 2021 Plan also provides for the issuance of restricted shares, the grant of RSUs and the issuance or grant of
other equity-based awards.

On November 20, 2024, the Board approved an
increase of 337,090 ordinary shares issuable pursuant to the 2021 Plan. As of March 17, 2025, options to purchase 772,974ordinary shares,
having a weighted average exercise price of $14.07 per share, and 16,070 RSUs, having no exercise